Haemoglobin Concentration on COVID-19

September 13, 2020 updated by: Mehmet Akif Yazar, Nevsehir Public Hospital

An Important Index on Severity of Coronavirus Disease: Erythrocyte Haemoglobin Concentration

A rapid oxygen desaturation has observed in patients with COVID-19 which have seriously respiratory failure and most of them have intubated and connected to the mechanical ventilator. Finally, many of them have died during the process.

ORF8 and superficial glycoproteins of a novel coronavirus bind to porphyrin on haemoglobin molecules and inhibit heme metabolism in an erythrocyte. However, it is not clarify the effects of the novel coronavirus on mean corpuscular volume (MCV), mean corpuscular of haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC).

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

In late December 2019, cases of pneumonia of unknown etiology began to appear in Wuhan, Hubei, China. This disease, which was named COVID-19 by the World Health Organization (WHO) on February 11, 2020, was identified as serious acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The disease, which spread rapidly from person to person, quickly became a pandemic in the world.

Some of the patients who admitted with high fever, cough and respiratory distress have been curing in intensive care units due to severe respiratory failure. A rapid oxygen desaturation has observed in these patients, and most of the patients have intubated and connected to the mechanical ventilator, but many of them have died in this process. Until May 02, 2020, approximately 3,5 million COVID-19 cases were detected throughout the world and nearly 250 thousand people died.

In this process, to identfy the reasons of the respiratory failure and oxygen desaturation has a high scientific value. Alveolar edema and reactive pneumocyte hyperplasia accompanied by inflammatory infiltration in the lung during the early stage of infection may cause disruption of oxygen transport. In some cases, the alveolar exudate organization and pulmonary interstitial fibrosis accompany this process, and the desquamation of the mucosal epithelium and the bronchi are covered with a mucous plug. The resulting destruction is thought to cause desaturation by affecting oxygen transport.

A novel coronavirus has a positive stranded RNA nucleic acid. In addition to its structural spikes, envelope and membrane proteins, it has non-structural proteins such as ORF1ab, ORF3a, ORF6, ORF7a, ORF10 and ORF8. Inhibitory effects of these proteins on haemoglobin may be a reason for rapid desaturation. By binding to the porphyrin of ORF8 and superficial glycoproteins on the hemoglobin, it inhibits the "heme" metabolism and patients' haemoglobin levels may be low. However, it is not clear the effects of the disease on mean corpuscular volume (MCV), mean corpuscular of haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC). Demonstrating the relationship between these parameters and the severity of the disease is of great importance in the treatment of the disease in terms of further studies.

The aim of this study is to reveal the effects of the disease on erythrocyte indices and to show the effectiveness of erythrocyte indices in predicting the severity of the disease.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients who applied to the hospital for a coronavirus disease symptom and whose covid-19 test was positive

Description

Inclusion Criteria:

  • All patients with COVID-19 test (+) using the PCR technique

Exclusion Criteria:

  • Those receiving blood products or any drugs that will affect their blood values before admission
  • Those patient with any hematologic diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group OP
outpatients with asymptomatic or uncomplicated or mild pneumonia
RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
Group H
hospitalized patients
RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
Group IC
patients admitted to intensive care unit
RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relationship between severity of disease and values of erythrocyte indices
Time Frame: 5 days
The severity of disease can decrease haemoglobin concentration and destroy oxygen transport.
5 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensitivity of haemoglobin concentration on severity of the disease
Time Frame: 5 days
Detecting of cut-off value of haemoglobine indices can predict severity of the disease
5 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 1, 2020

Primary Completion (Anticipated)

November 20, 2020

Study Completion (Anticipated)

December 30, 2020

Study Registration Dates

First Submitted

May 4, 2020

First Submitted That Met QC Criteria

May 4, 2020

First Posted (Actual)

May 6, 2020

Study Record Updates

Last Update Posted (Actual)

September 16, 2020

Last Update Submitted That Met QC Criteria

September 13, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Corona Virus Infection

Clinical Trials on File scanning

Subscribe